George A. Digenis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
George A. Digenis has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Alan F. Parr
Glaxo-Wellcome, Research Triangle Park, North Carolina 27709, USA
1 shared publicationCraig McClain
University of Kentucky A.B. Chandler Medical Center
1 shared publicationE. P. Sandefer
University of Kentucky
1 shared publicationErik P. Sandefer
University of Kentucky
1 shared publicationGustavo F. Doncel
Medical School
1 shared publicationKazuya Matsumoto
Santen Pharmaceutical Co. Ltd, Osaka 562-0026, Japan
1 shared publication
Latest Publications
- 1 September 2003
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 4 (3) , 10-17
Coprecipitation of nonoxynol-9 with polyvinylpyrrolidone to decrease vaginal irritation potential while maintaining spermicidal potency
The aim of this study was to test the hypothesis that polyvinylpyrrolidone (PVP) would increase the critical micelle concentration (CMC) of nonoxynol-9 (N-9), providing a reduction in its irritation potential, while maintaining essential spermicidal activity. Solid coprecipitates of N-9 with PVP were manufactured with the use of a modified lyophilization process. The irritation potential of N-9 was estimated by an in vitro assay, monitoring the extent of hemolysis of red blood cells. CMCs of N-9 were measured in the presence of various concentrations of PVP. A modified Sander-Cramer assay was implemented to measure the spermicidal activity of N-9 and the N-9/PVP coprecipitates. With the use of the lyophilization process and more suitable solvents, solid coprecipitates of N-9/PVP were manufactured with no residual organic solvents. The irritation potential of N-9 was reduced when in the presence of PVP-50% hemolysis values increased from 0.054 mM to more than 0.2mM. N-9 CMC values increased in the presence of PVP from 0.085 mM (0% PVP) to 0.110 mM (3.5% PVP) and 0.16 6mM (10% PVP). However, spermicidal activities ranged from 0.213 mM to 0.238 mM, N-9 remaining steady regardless of the amount of PVP. By use of N-9/PVP coprecipitates, the self-association properties and irritation potentials of N-9 were altered. This result suggests a process to produce a spermicidal product that reduces the detrimental implications to the vaginal epithelium while maintaining the essential spermicidal activity.
- 1 September 2003
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 4 (3) , 10-17
Coprecipitation of nonoxynol-9 with polyvinylpyrrolidone to decrease vaginal irritation potential while maintaining spermicidal potency
The aim of this study was to test the hypothesis that polyvinylpyrrolidone (PVP) would increase the critical micelle concentration (CMC) of nonoxynol-9 (N-9), providing a reduction in its irritation potential, while maintaining essential spermicidal activity. Solid coprecipitates of N-9 with PVP were manufactured with the use of a modified lyophilization process. The irritation potential of N-9 was estimated by an in vitro assay, monitoring the extent of hemolysis of red blood cells. CMCs of N-9 were measured in the presence of various concentrations of PVP. A modified Sander-Cramer assay was implemented to measure the spermicidal activity of N-9 and the N-9/PVP coprecipitates. With the use of the lyophilization process and more suitable solvents, solid coprecipitates of N-9/PVP were manufactured with no residual organic solvents. The irritation potential of N-9 was reduced when in the presence of PVP-50% hemolysis values increased from 0.054 mM to more than 0.2mM. N-9 CMC values increased in the presence of PVP from 0.085 mM (0% PVP) to 0.110 mM (3.5% PVP) and 0.16 6mM (10% PVP). However, spermicidal activities ranged from 0.213 mM to 0.238 mM, N-9 remaining steady regardless of the amount of PVP. By use of N-9/PVP coprecipitates, the self-association properties and irritation potentials of N-9 were altered. This result suggests a process to produce a spermicidal product that reduces the detrimental implications to the vaginal epithelium while maintaining the essential spermicidal activity.
- 8 October 2002
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 29 (7) , 771-775
Synthesis of novel iodinated derivatives of nonoxynol-9 and their bioavailability in rats
- 8 October 2002
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 29 (7) , 771-775
Synthesis of novel iodinated derivatives of nonoxynol-9 and their bioavailability in rats
- 1 January 2000
- Published by Springer Nature in Pharmaceutical Research
- Vol. 17 (5) , 572-582
Bioequivalence Study of Stressed and Nonstressed Hard Gelatin Capsules Using Amoxicillin as a Drug Marker and Gamma Scintigraphy to Confirm Time and GI Location of In Vivo Capsule Rupture
Purpose: Evaluate if crosslinked hard gelatin capsules (HGCs) havingdifferent in vitro dissolution profiles changed in vivorelease times oraltered bioavailability of a drug marker; assess if a...
- 1 January 2000
- Published by Springer Nature in Pharmaceutical Research
- Vol. 17 (5) , 572-582
Bioequivalence Study of Stressed and Nonstressed Hard Gelatin Capsules Using Amoxicillin as a Drug Marker and Gamma Scintigraphy to Confirm Time and GI Location of In Vivo Capsule Rupture
Purpose: Evaluate if crosslinked hard gelatin capsules (HGCs) havingdifferent in vitro dissolution profiles changed in vivorelease times oraltered bioavailability of a drug marker; assess if a...
- 1 January 1999
- Published by Springer Nature in Pharmaceutical Research
- Vol. 16 (2) , 266-271
Evaluation of the Feasibility and Use of a Prototype Remote Drug Delivery Capsule (RDDC) for Non-Invasive Regional Drug Absorption Studies in the GI Tract of Man and Beagle Dog
Purpose. Evaluate a prototype Remote Drug Delivery Capsule (RDDC) for use in beagle dogs and human volunteers for non-invasive drug absorption studies in different regions of the gastrointestinal...
- 1 January 1999
- Published by Springer Nature in Pharmaceutical Research
- Vol. 16 (2) , 266-271
Evaluation of the Feasibility and Use of a Prototype Remote Drug Delivery Capsule (RDDC) for Non-Invasive Regional Drug Absorption Studies in the GI Tract of Man and Beagle Dog
Purpose. Evaluate a prototype Remote Drug Delivery Capsule (RDDC) for use in beagle dogs and human volunteers for non-invasive drug absorption studies in different regions of the gastrointestinal...